APTAMER WHICH SELECTIVELY BINDS TO ERBB2 RECEPTOR AND USES THEREOF

• Main Authors: KIM, JONG IN, KANG, HYUNGU, KIM, KI SEOK, JANG, SUNG KEY, OH, IL UNG, CHOI, MIN JEONG, KANG, WOON JUN, CHAE, YOUNG CHAN, KIM, YOUNDONG, LEE, JUNG HWAN, IM, JONG HUN
• Format: Patent
• Language: English; French; Korean
• Published: 27.12.2012
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present invention relates to a DNA aptamer which selectively binds to a breast cancer-related Her2 (ERBB2) receptor, and a composition for inhibiting cancer metastasis and a composition for diagnosing cancer which contain the DNA aptamer as an active ingredient, wherein the aptamer has a binding mechanism different from existing antibodies and thus can more effectively inhibit cancer metastasis and diagnose cancer. La présente invention concerne un aptamère d'ADN qui se lie sélectivement à un récepteur Her2 associé au cancer du sein (ERBB2) et une composition pour l'inhibition de la métastase du cancer et une composition pour le diagnostic du cancer qui contient l'aptamère d'ADN en tant que principe actif, l'aptamère ayant un mécanisme de liaison différent des anticorps existants et, par conséquent, pouvant plus efficacement inhiber la métastase du cancer et diagnostiquer le cancer.